Outsourcing a cardiovascular program means sourcing CRO and CDMO partners for cardiac-specific in vivo models (heart failure, atherosclerosis, arrhythmia, thrombosis), telemetry and hERG cardiac-safety work, DMPK, cardiac imaging core labs, ECG and biomarker analysis, and large outcomes-trial operations. BioBridgeX is a neutral marketplace: free for buyers, a flat 2% supplier fee, and you compare quotes and contract directly with your chosen suppliers.
Cardiovascular CRO and CDMO vendors (85)
UNIQ Trials
Apeloa Pharmaceutical
VCHP Clinical Solutions
AAPharmaSyn
Famar Group
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Siegfried Holding
CRO & CDMO · Drug Substance: Small Molecule / API, Formulation Development, LNP / Delivery Formulation
Aenova Group
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
Fresenius Kabi Contract Manufacturing
CDMO · Formulation Development, LNP / Delivery Formulation, Process Development
WuXi STA (STA Pharmaceutical)
CDMO · Peptide / Oligo Synthesis, Drug Substance: Small Molecule / API, ADC / Bioconjugation
Agilent Technologies
CDMO · Peptide / Oligo Synthesis, Process Development, Analytical Development
ST Pharm
CDMO · Peptide / Oligo Synthesis, mRNA / RNA Manufacturing, Process Development
Nitto Avecia Pharma Services
CDMO · Peptide / Oligo Synthesis, Process Development, Analytical Development
WuXi TIDES (WuXi AppTec)
CRO & CDMO · Peptide / Oligo Synthesis, ADC / Bioconjugation, Medicinal & Synthetic Chemistry
Teva API (TAPI)
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Almac Group
CRO & CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Onyx Scientific (IPCA)
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Laurus Labs (Laurus Synthesis)
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
F.I.S. (Fabbrica Italiana Sintetici)
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
PROCOS
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Sumitomo Chemical (Pharmaceuticals/CDMO)
CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Fermion (Orion Corporation)
CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Minakem (Minafin Group)
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Curia (formerly AMRI)
CRO & CDMO · Target ID & Validation, Hit-to-Lead, Lead Optimization
Bachem
CDMO · Peptide / Oligo Synthesis, Process Development, Analytical Development
AMPAC Fine Chemicals (SK pharmteco)
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Veranova
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Pfizer CentreOne
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Thermo Fisher Scientific (Patheon)
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Divi's Laboratories
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Dr. Reddy's Custom Pharma Services (CPS)
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Piramal Pharma Solutions
CRO & CDMO · Hit-to-Lead, Lead Optimization, Medicinal & Synthetic Chemistry
EUROAPI
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Seqens
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Olon Group
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
DOTTIKON ES
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
CordenPharma
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Sterling Pharma Solutions
CDMO · Medicinal & Synthetic Chemistry, Process Development, Drug Substance: Small Molecule / API
Siegfried
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Cambrex
CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
QPS Holdings
CRO · Bioanalytical Services, DMPK / ADME, GLP Toxicology
Simulations Plus
CRO · PK/PD & Modeling, DMPK / ADME, In Vitro / Early Toxicology
Certara
CRO · PK/PD & Modeling, Biostatistics & Statistical Programming, Medical Writing
Labcorp
CRO & CDMO · Central Laboratory Services, GLP Toxicology, Safety Pharmacology
Pharmacology Discovery Services (PDS)
CRO · In Vitro Pharmacology, Safety Pharmacology, Assay Development & Screening
Labcorp (Labcorp Drug Development)
CRO · In Vitro Pharmacology, DMPK / ADME, GLP Toxicology
WuXi AppTec (WuXi Biology)
CRO & CDMO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
Syngene International
CRO & CDMO · GLP Toxicology, Safety Pharmacology, DMPK / ADME
Sai Life Sciences
CRO & CDMO · DMPK / ADME, In Vitro / Early Toxicology, GLP Toxicology
KCAS Bio
CRO · Bioanalytical Services, Biomarker Discovery & Development, Immunogenicity & Immunotoxicology
IQVIA Laboratories (Q2 Solutions)
CRO · Bioanalytical Services, Biomarker Discovery & Development, DMPK / ADME
Nuvisan
CRO & CDMO · DMPK / ADME, Bioanalytical Services, In Vitro / Early Toxicology
Biotrial
CRO · Safety Pharmacology, GLP Toxicology, Toxicokinetics (TK)
Scantox
CRO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Cyprotex (an Evotec company)
CRO · In Vitro / Early Toxicology, DMPK / ADME, Genetic Toxicology
Evotec
CRO & CDMO · In Vitro / Early Toxicology, DMPK / ADME, Safety Pharmacology
Frontage Laboratories
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Toxicokinetics (TK)
Eurofins Discovery
CRO · In Vitro / Early Toxicology, Safety Pharmacology, DMPK / ADME
WuXi AppTec
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Inotiv
CRO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Labcorp (Labcorp Drug Development / former Covance)
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Charles River Laboratories
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
Cromos Pharma
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
George Clinical (Emerald Clinical)
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Cytel
CRO · Biostatistics & Statistical Programming, Clinical Data Management, Clinical Operations
Pharmaron
CRO & CDMO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Tigermed
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
CMIC Group
CRO & CDMO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Altasciences
CRO & CDMO · Phase 1 / Early Clinical Unit, Clinical Operations, Bioanalytical Services
Celerion
CRO · Phase 1 / Early Clinical Unit, Clinical Operations, Bioanalytical Services
ClinChoice
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Emmes
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
ProPharma
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Novotech
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Premier Research
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Caidya
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
PSI CRO
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Worldwide Clinical Trials
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Syneos Health
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Medpace
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Fortrea
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
PPD (Thermo Fisher Scientific)
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Parexel
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
ICON plc
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
IQVIA
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
What kind of CRO work does a Cardiovascular program need?
Cardiovascular covers a wide spread of biology, and the outsourcing you need bends hard to which corner you are in. A heart failure program leans on different models and endpoints than an antithrombotic, an antihypertensive, a lipid-lowering agent, a PAH drug, or an antiarrhythmic. The first thing a good CRO partner does is map your indication to the right disease model and the right readout, because a supplier that is excellent at atherosclerosis plaque work may have never run a pressure-overload heart failure study.
On the preclinical side, the in vivo menu is where cardiovascular gets specific. Heart failure programs commonly use transverse aortic constriction (TAC) for pressure overload, coronary ligation or ischemia-reperfusion for post-MI remodeling, and isoproterenol challenge for acute stress. Atherosclerosis work runs in ApoE-knockout or LDLR-knockout mice on a high-fat diet, with plaque burden and lesion histology as the readout. Antithrombotics need arterial and venous thrombosis models plus bleeding-time assays to show the therapeutic window. Hypertension and PAH programs use telemetered animals for continuous blood pressure, and right-heart catheterization for pulmonary pressures. Functional readouts like echocardiography (ejection fraction, fractional shortening), invasive pressure-volume loops, and cardiac biomarkers (NT-proBNP, troponin) carry the efficacy story.
Cardiac safety deserves its own line, because it is unusually central in this therapeutic area and it matters for every drug, not just cardiovascular ones. The hERG patch-clamp or automated ion-channel panel, in vivo QT studies in telemetered large animals, and increasingly the CiPA assays (multi-ion-channel plus stem-cell-derived cardiomyocyte work) sit at the front of the program. DMPK and bioanalytical round out preclinical the same way they do elsewhere. On the clinical side, cardiovascular is defined by scale: outcomes trials (CVOTs) measuring MACE often enroll thousands of patients across many countries and run for years, so you are buying clinical operations, an ECG and Holter core lab, a cardiac imaging core lab (echo and cardiac MRI), an independent clinical events committee for endpoint adjudication, biostatistics built for time-to-event analysis, and pharmacovigilance, frequently with a DSMB. Cardiac imaging core labs and event adjudication are two services that are nearly unique to how this area runs.
How do you choose a CRO for Cardiovascular?
The headline rate is the least useful number in front of you. In cardiovascular, the questions that actually predict a clean program are about whether the team has run your specific model or your specific endpoint before, with their own historical control data, rather than standing one up for the first time on your budget. Score two or three candidates against the same written scope so you are comparing like for like, and weight the items below over price.
- Therapeutic-area and sub-indication experience: heart failure (HFrEF and HFpEF), hypertension, atherosclerosis and lipids, thrombosis, arrhythmia, PAH, and cardiomyopathy each behave differently. Ask for case studies in your exact sub-indication, not just "cardiovascular."
- Relevant disease models or patient access: for preclinical, confirm the model (TAC, ischemia-reperfusion, ApoE/LDLR atherosclerosis, thrombosis, telemetered hypertension) is already validated in-house with reference data. For clinical, ask about site networks and cardiologist investigators in the geographies and patient population you need, because slow enrollment, not study conduct, is what sinks outcomes trials.
- Cardiac safety capability: a validated hERG and ion-channel panel, in vivo telemetry for QT and blood pressure, and CiPA-aligned assays if your reviewers expect them. For the clinic, a centralized ECG and Holter core lab with the throughput your trial size demands.
- Imaging and endpoint adjudication: a cardiac imaging core lab (echocardiography, cardiac MRI) with standardized acquisition and central reads, plus an independent clinical events committee for adjudicating MACE and other hard endpoints. These keep your primary endpoint defensible to the FDA and EMA.
- Regulatory track record and data quality: a clean GLP record for the safety work, GCP-compliant systems and inspection history for the trial, CDISC-conformant data from day one, and biostatistics fluent in time-to-event and non-inferiority designs common to CVOTs.
- Capacity and turnaround: a strong lab booked solid for months can be slower than a good lab with an open slot. Confirm real availability, report turnaround, and how change orders are priced when a study slips or a protocol amends, because in long cardiovascular trials amendments are close to inevitable.
Frequently asked questions
What preclinical models are used for cardiovascular drug development?
Why is cardiac safety testing so important, even for non-cardiovascular drugs?
What is a cardiovascular outcomes trial (CVOT) and what does it cost to run?
Do I need a separate CRO for cardiac imaging and event adjudication?
What endpoints and biomarkers matter most in cardiovascular trials?
Is sourcing cardiovascular CRO and CDMO services on BioBridgeX free for buyers?
Source Cardiovascular work with one contract
Compare transparent quotes from qualified Cardiovascular CRO and CDMO vendors, then contract once. Free for buyers.
Compare quotes